 CAMBRIDGE, Mass. BEIJING--BUSINESS WIRE--- BGNE BTKi--BeiGene, Ltd. NASDAQ: BGNE; HKEX: 06160, a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that BRUKINSA zanubrutinib has received conditional approval from the China National Medical Products Administration NMPA for the treatment of adult patients with Waldenströms macroglobulinemia WM who have received at least one prior therapy. The supplemental new drug application w 